Compare ISTR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISTR | LCTX |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.5M | 388.6M |
| IPO Year | 2014 | 1996 |
| Metric | ISTR | LCTX |
|---|---|---|
| Price | $28.54 | $1.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $31.50 | $6.25 |
| AVG Volume (30 Days) | 126.1K | ★ 1.4M |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $66.56 | $109.40 |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $37.13 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $17.89 | $0.64 |
| 52 Week High | $30.49 | $2.09 |
| Indicator | ISTR | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 40.54 |
| Support Level | $26.18 | $1.14 |
| Resistance Level | $28.84 | $1.31 |
| Average True Range (ATR) | 0.50 | 0.08 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 72.19 | 31.67 |
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashier's checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.